Recce Pharmaceuticals Ltd. announced the Intellectual Property Department of the Hong Kong Special Administrative Region has granted Patent Family 3 "Anti-Virus Agent and Method for Treatment of Viral Infection", furthering marketing and manufacturing monopolies to February 2037. The Intellectual Property Department of the Hong Kong Special Administrative Region has granted claims relating to RECCE® 327 (R327) and Anti-Viral formulation RECCE® 529 (R529), most notably: Composition/method of manufacture of RECCE® anti-infectives. Use of R327 or R529 for the treatment of viruses having a lipid envelope or coat, examples being SARS-CoV-2 and Corona viruses, Influenza viruses, HIV, Hepatitis, Ross River and Herpes viruses.

Administration of R327 or R529 by oral, injection, inhalation and transdermal dose applications.